Imatinib (Gleevec / Glivec)
A BCR-ABL and KIT tyrosine kinase inhibitor for chronic myeloid leukaemia, GIST, and Ph+ ALL, and one of the first true precision cancer medicines.
What is Imatinib?
What it targets
The BCR-ABL oncoprotein from the Philadelphia chromosome, and the KIT and PDGFR kinases. Blocking these stops cancer cells from receiving constant growth signals.
Who it may help
Patients with Ph+ CML, Ph+ ALL, KIT-positive GIST, and selected rare tumours such as dermatofibrosarcoma protuberans and PDGFR-driven blood disorders.
Why testing matters
Molecular or genetic testing must confirm the target before treatment. Without a confirmed BCR-ABL or KIT abnormality, imatinib is unlikely to help.
Which cancers can Imatinib treat?
Imatinib is approved or used in the following cancers where a specific molecular target is confirmed, usually as part of a clear treatment plan.
| Chronic myeloid leukaemia (CML) | A long-standing treatment for Philadelphia chromosome-positive CML, especially chronic phase. Newer TKIs, including asciminib approved first-line in 2024, are alternatives in some patients. |
| Philadelphia chromosome-positive ALL | Used together with chemotherapy in Ph+ ALL, where adding imatinib significantly improves remission rates compared with chemotherapy alone. |
| Gastrointestinal stromal tumour (GIST) | Used for KIT-positive unresectable or metastatic GIST, and after surgery as adjuvant therapy in selected higher-risk patients. |
| Myelodysplastic / myeloproliferative disease | Used in selected patients whose disease is driven by PDGFR gene rearrangements. |
| Dermatofibrosarcoma protuberans (DFSP) | Considered in unresectable, recurrent, or metastatic DFSP, a rare skin tumour often driven by PDGFRB fusions. |
| Other rare kinase-driven conditions | May be used in selected hypereosinophilic syndrome, chronic eosinophilic leukaemia, or aggressive systemic mastocytosis when the underlying kinase abnormality is sensitive. |
Are you eligible for Imatinib?
Eligibility depends on a confirmed molecular target, the cancer type and phase, and organ function. Imatinib is only suitable when the correct target is confirmed.
- Philadelphia chromosome-positive CML confirmed by cytogenetics or FISH
- BCR-ABL1 fusion gene confirmed by PCR for CML or Ph+ ALL
- KIT-positive GIST confirmed by immunohistochemistry and mutation testing
- PDGFR gene rearrangement confirmed for selected MDS/MPN, DFSP, or related conditions
- Adequate liver function, since imatinib is processed by the liver
- Adequate kidney function and blood counts for standard dosing
- No severe allergy to imatinib or to any tablet ingredient
- Not pregnant, with effective contraception in place during treatment
- Able to take and absorb oral tablets reliably and attend regular monitoring
How does Imatinib work?
- Identifying the target
- Blocking the switch
- Cancer cells stop growing
- Healthy cells are largely spared
Imatinib was the first successful targeted cancer therapy and remains a landmark proof that precision oncology can transform an aggressive cancer into a manageable condition.
Tests required before starting Imatinib
These tests confirm the diagnosis and target, guide dosing, and set a baseline for monitoring response and side effects.
| BCR-ABL PCR (quantitative) | Confirms the BCR-ABL1 fusion and sets the baseline transcript level used to track response at 3, 6, and 12 months in CML. |
| Cytogenetics / FISH | Detects the Philadelphia chromosome at diagnosis and helps assess early response. |
| KIT and PDGFRA mutation testing | For GIST, confirms KIT positivity and identifies the specific exon mutation, which predicts how well imatinib is likely to work. |
| Complete blood count (CBC) | Baseline white cell, platelet, and haemoglobin counts, monitored closely during the early weeks of treatment. |
| Liver function tests | Imatinib is processed by the liver, so raised enzymes may need dose adjustment or closer monitoring. |
| Kidney function and electrolytes | Help guide safe dosing and assess the risk of fluid retention. |
| Pregnancy test where relevant | Imatinib can harm an unborn baby, so pregnancy must be excluded before starting in women of childbearing age. |
How is Imatinib given?
Imatinib is taken by mouth at home and does not need a hospital infusion. The dose depends on the disease, phase, response, and tolerance.
| Dose for CML chronic phase | Usually 400 mg once daily, adjusted by the oncologist based on response and side effects. |
| Dose for CML advanced phase | Often higher, around 600 to 800 mg daily in divided doses, depending on the situation. |
| Dose for GIST | Commonly 400 mg once daily, sometimes increased to 800 mg if the disease does not respond, and given for about 3 years in the adjuvant setting. |
| How to take | Swallow the tablet whole with a large glass of water and a meal to reduce stomach upset. Do not crush or open the tablet. |
| Timing | Take at the same time each day. If a twice-daily dose is prescribed, space the doses about 12 hours apart. |
| Missed dose | Take it on the same day as soon as you remember. If it is already the next day, skip it and continue as normal. Do not double up. |
| Duration | In CML, treatment usually continues long term. In GIST, it continues for a set adjuvant period or until the disease progresses or side effects become unacceptable. |
Clinical evidence and benefits
Imatinib produced results that were remarkable at launch and have held up across more than two decades of follow-up, supported by landmark trials.
| Long-term control in CML | The IRIS trial and its long follow-up showed that imatinib turned chronic phase CML from a frequently fatal disease into a long-term, manageable condition for the majority of patients. |
| Deep molecular responses | Many patients reach a major molecular response over the first one to two years, measured by falling BCR-ABL levels on PCR. |
| Possibility of treatment-free remission | Selected patients with a sustained deep response may, under close monitoring, attempt stopping treatment, with a meaningful proportion staying in remission. |
| Benefit in GIST | Imatinib produces durable disease control in KIT-positive metastatic GIST and, given after surgery, reduces recurrence in higher-risk disease, supported by ACOSOG Z9001 and SSG XVIII. |
| Benefit in Ph+ ALL | Adding imatinib to chemotherapy significantly improves remission rates and outcomes in Philadelphia chromosome-positive ALL. |
| Oral and outpatient | As a once or twice daily tablet, imatinib lets most patients continue normal life with regular outpatient monitoring rather than hospital admission. |
Individual responses vary with disease phase, mutation profile, prior treatment, adherence, and overall health. These reflect published clinical trial and real-world data.
Side effects of Imatinib
Imatinib is generally better tolerated than chemotherapy, but side effects are common and need monitoring. Most are mild to moderate and manageable.
| Nausea or vomiting | Common, and usually eased by taking the tablet with food; anti-nausea medicine can be added if needed. |
| Fluid retention and swelling | Puffiness around the eyes and swelling of the ankles are common; usually mild, but report rapid or severe swelling. |
| Fatigue | Common, often mild to moderate, and frequently improves after the first few weeks. |
| Muscle cramps | Frequent, especially at night; calcium or magnesium supplements may help on your doctor's advice. |
| Diarrhoea | Common and usually manageable with diet and simple medication. |
| Skin rash | A mild rash is fairly common and often settles with antihistamines; severe rash should be reported promptly. |
| Low white cells (neutropenia) | Common; counts are monitored and the dose may be paused or adjusted if they drop too low. |
| Low platelets or anaemia | Can occur, raising the risk of bruising, bleeding, or tiredness; blood counts are checked regularly. |
| Liver enzyme changes | Usually mild and reversible; significant liver problems are uncommon but liver tests are monitored. |
Contact your doctor immediately if you develop:
- Sudden or severe swelling of the face, around the eyes, or in the hands and feet
- Shortness of breath, chest tightness, or difficulty breathing
- Yellowing of the eyes or skin, dark urine, or severe abdominal pain
- Unusual bruising, bleeding, or black or bloody stools
- High fever or chills, especially with a very low white cell count
Safety precautions and drug interactions
Tell your oncologist and pharmacist about your full medical history, all medicines and supplements, and any herbal products, because imatinib has important interactions.
- CYP3A4 inhibitors such as ketoconazole, clarithromycin, and grapefruit can raise imatinib levels and increase toxicity
- CYP3A4 inducers such as rifampicin, carbamazepine, phenytoin, and St John's Wort can lower imatinib levels and reduce its effect
- Imatinib can raise the levels of some co-processed medicines, including simvastatin, so these may need review
- The interaction with warfarin is significant, so a low-molecular-weight heparin is usually preferred for blood thinning
- Pregnancy should be avoided because imatinib can cause serious harm to an unborn baby
- Breastfeeding is not advised, since imatinib passes into breast milk
- Live vaccines should generally be avoided during treatment; ask your team before any vaccination
- Tell your team about liver disease, heart disease, kidney disease, or a history of serious infections
Imatinib combination treatments
Imatinib is often used on its own in CML, but it is combined with other treatments in several settings to improve outcomes.
| Imatinib + chemotherapy (Ph+ ALL) | Combined with induction and ongoing chemotherapy in Ph+ ALL, significantly improving remission rates over chemotherapy alone. |
| Imatinib + stem cell transplant | Used around allogeneic transplant in high-risk CML or Ph+ ALL, as a bridge before transplant or as maintenance after it. |
| Imatinib + surgery (GIST) | Given before surgery to shrink some tumours, or after surgery as adjuvant therapy to reduce recurrence in higher-risk KIT-positive GIST. |
| Switching to other TKIs | If resistance or intolerance develops in CML, dasatinib, nilotinib, bosutinib, ponatinib, or asciminib may be used depending on the mutation profile. |
| Next-line therapy in GIST | If GIST progresses, options include sunitinib, regorafenib, ripretinib, or avapritinib for selected PDGFRA D842V tumours. |
If Imatinib stops working
Some cancers become resistant to imatinib over time. Understanding why guides the next step, and adherence is always checked first.
| Missed doses | Inconsistent dosing is the most common reason for an apparent loss of response, so adherence is reviewed before any change in treatment. |
| BCR-ABL mutations | Mutations in the BCR-ABL kinase, such as Y253H or E255K, can reduce imatinib binding; mutation testing identifies which next TKI is most likely to work. |
| T315I, the gatekeeper mutation | This mutation defeats first and second-generation TKIs; ponatinib or asciminib are the usual options when it is present. |
| Re-testing at progression | Blood and bone marrow markers are repeated in CML, and mutation testing and imaging are reviewed in GIST, to reassess risk and direction. |
| Next-line options | These include other TKIs, and in CML, asciminib, a newer agent that binds a different pocket on BCR-ABL and is now also approved first-line. |
| GIST resistance | KIT exon 9 or secondary mutations may need a switch to sunitinib, then regorafenib or ripretinib, with avapritinib for PDGFRA D842V disease. |
Cost of Imatinib by country
Imatinib is now off-patent in most markets, so widely available generics make this once very expensive medicine far more affordable. Always ask for a full written estimate.
| India | Quality-assured generics from several manufacturers are available at a fraction of the original branded price. Branded Glivec is also available, and patient-support routes may help. Ask for a per-month estimate. |
| China | Generic and branded imatinib are used in leading cancer hospitals, with access and price depending on hospital procurement and insurance category. CancerFax can help check practical access. |
| USA | Generic imatinib is far cheaper than branded Gleevec, which has a high list price without insurance. Most patients are covered through insurance, and patient-assistance programmes may apply. |
| UK / Europe | Available through national health systems for approved indications, usually with little or no out-of-pocket cost for covered patients; self-pay costs are higher. |
Availability of Imatinib globally
Imatinib is available in most major markets in both branded and generic forms, though brand, strength, and price vary by country and hospital.
India
Widely available as generic imatinib from several manufacturers, and as branded Glivec through patient-support routes. Stocked at major cancer centres. CancerFax can help check access and second-opinion pathways.
China
Used in leading cancer hospitals for CML and GIST, in generic and branded forms. Access depends on hospital procurement and insurance category. CancerFax supports patients exploring care in Chinese oncology centres.
USA
Generic imatinib is available at major pharmacies, with branded Gleevec also sold. Patient-assistance programmes exist for eligible uninsured patients.
Europe
Generic imatinib is standard CML therapy and is covered by national health systems across the EU and UK for approved indications.
Imatinib in current clinical trials
Although imatinib is a mature standard therapy, research continues into stopping treatment safely, refining who benefits most, and combining or sequencing it with newer agents.
| Treatment-free remission | Studies continue to define which CML patients can safely stop imatinib after a sustained deep response, and how best to monitor them. |
| Optimising GIST therapy | Trials explore adjuvant duration, dosing by mutation type, and sequencing with newer KIT and PDGFRA inhibitors. |
| Sequencing with newer agents | Research looks at how imatinib fits alongside newer options such as asciminib in CML and next-generation inhibitors in GIST. |
Your treatment journey with Imatinib
Diagnosis and molecular testing
Specialist consultation and planning
Starting treatment
Early response monitoring
Ongoing monitoring
If resistance or intolerance develops
Questions to ask your oncologist about Imatinib
- Has my BCR-ABL or KIT result been confirmed, and what does it mean for me?
- Should I be on Imatinib or a newer TKI?
- What response should I expect at 3, 6, and 12 months?
- How often will I need blood tests and PCR monitoring?
- Can I ever stop taking Imatinib?
- What foods, supplements, or medicines should I avoid?
- What should I do if I miss a dose?
- Is generic Imatinib right for me, and what are my options if it stops working?
How CancerFax supports Imatinib patients
CancerFax helps CML and GIST patients and families understand their reports, weigh their options, and access the right treatment with confidence.
| Report review | Upload your BCR-ABL PCR, bone marrow, KIT mutation, biopsy, or blood count reports, and our team reviews them and explains what they mean for imatinib and other options. |
| Specialist connection | We connect patients with haematologists and oncologists experienced in CML and GIST targeted therapy in India, China, and other centres. |
| Second opinion | If you are unsure about your regimen, or the disease has relapsed or become resistant, CancerFax arranges an expert second opinion. |
| Access and cost navigation | We help check practical availability and legitimate generic sourcing across India and other markets, and provide per-month cost estimates where possible. |
| Advanced therapy guidance | For complex, resistant, or advanced disease, CancerFax helps explore newer TKIs, clinical trials, and specialist care across the China corridor and beyond. |
Frequently asked questions about Imatinib
Common questions from patients and caregivers
Imatinib is a targeted therapy — it blocks a specific abnormal protein called BCR-ABL that drives cancer cell growth in CML, rather than broadly killing fast-dividing cells. This precision means common chemotherapy side effects like hair loss and severe nausea are uncommon. It works as an oral tablet taken at home, not as an IV infusion.
In CML, response is tracked at standard milestones. Blood counts often normalise within the first few months, and BCR-ABL levels measured by PCR are checked at 3, 6, and 12 months. In GIST, response is usually judged by imaging at 3 to 6 months. Your oncologist will explain your own targets and what your results mean.
Imatinib has important drug interactions. Medicines and foods that affect the CYP3A4 enzyme, including some antibiotics, antifungals, seizure medicines, and grapefruit, can raise or lower imatinib levels. The interaction with warfarin is significant, so a different blood thinner is usually preferred. Show your oncologist and pharmacist a full list of everything you take, including vitamins and herbal products.
Yes — multiple real-world studies have confirmed equivalent clinical outcomes between generic imatinib and branded Gleevec/Glivec. The active ingredient, dose, and bioavailability are the same. Generic imatinib is endorsed by major oncology guidelines including NCCN and ELN and is dramatically more affordable in most markets.
Treatment-free remission (TFR) is possible for carefully selected CML patients who have been on imatinib for at least 5 years AND have maintained a deep molecular response (MR4 or MR4.5) for at least 2 years. About 40–60% of eligible patients can maintain remission off treatment. TFR must only be attempted with monthly BCR-ABL PCR monitoring — never stop imatinib without your oncologist's guidance and a monitoring plan in place.
If BCR-ABL levels stop falling or start rising, your oncologist will first check whether you have been taking the drug consistently (adherence is the most common reason for resistance). If true resistance is confirmed, BCR-ABL kinase domain mutation testing is performed to identify the specific mutation. Most mutations respond to second-generation TKIs (dasatinib, nilotinib, bosutinib). The T315I mutation requires ponatinib or asciminib. Switching is standard practice and many patients achieve deep responses on second-line TKIs.
No — imatinib is classified as Pregnancy Category D (US) and causes serious foetal harm. Effective contraception is required throughout treatment. Women who wish to become pregnant should discuss this with their oncologist — in some cases, treatment-free remission attempts or switching to a drug with a better pregnancy safety profile may be considered. Never stop imatinib without specialist guidance.
Yes. Imatinib is widely available in both India and China, in branded and generic forms, for CML, GIST, and other approved uses. Brand, strength, and price can vary by hospital and pharmacy. CancerFax can help you check practical availability, compare access options, and arrange a specialist second opinion across India, China, and other centres.